(Ref: Spotlight On Desk)
May 4th, 2020
By: Simon King
In this episode FirstWord Pharma PLUS executive editors Simon King and Michael Flanagan discuss new data for Gilead Sciences’ remdesivir showing that it accelerated the recovery time of hospitalised patients with advanced COVID-19 by 31%. They also analyse the race to develop an effective vaccine and breakdown the impact of the pandemic on pharma’s sales and operating performance.
Thanks for listening and please do forward any feedback and suggestions to simon.king@firstwordgroup.com
Stay safe
The FirstWord team
To read more Spotlight On articles, click here.
Share this Article
Related News
- FirstWord Pharma COVID-19 Podcast [06/04] - Assessing potential treatment approaches
- Physician Views: With Fovista in the spotlight, FirstWord is polling ophthalmologists to ask how OphthoTech's drug may shape the wet AMD market
- Spotlight On: Dissecting pharma's first major deal of 2017 – FirstWord discusses Ipsen's expansion in oncology with CEO David Meek
- Spotlight On Interview: A new benchmark in diabetes drug adherence? – FirstWord discusses the commercial strategy for Intarcia's implantable GLP-1 agonist with CEO Kurt Graves
- Spotlight On Interview: Genmab's collaborative outlook pays dividends – FirstWord speaks to CEO Jan van de Winkel
Reference Articles
Recent Reports
- Trends in Digital Patient Engagement (2020) (Ref. FirstWord Dossier)
- Head and Neck Squamous Cell Carcinoma: KOL Insight (2020) (Ref. FirstWord Therapy Trends)
- Pricing and Reimbursement in Oncology: Payer Views (2020) (Ref. FirstWord Dossier)